Fischer Medical Ventures Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Fischer Medical Ventures Ltd trades at ₹39.4, in a downtrend and 33 weeks into that stage. That is −18.1% against its own 200-day average. It sits at 9% of a 52-week range of ₹31 to ₹118. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.

Today the stock is in a downtrend — week 33 of stage 4, confirmed. At ₹39.4 it trades −18.1% versus its 200-day average and sits at 9% of its 52-week range (₹31–₹118).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +17,814% while the NIFTY 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 22nd percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Fischer Medical Ventures Ltd trades at 80.0× P/E, near the bottom of its own range — cheaper only 22% of the time. Its long-run median P/E is 1,598.4×, measured across 2.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 80.0× is near the bottom of its own range — cheaper only 22% of the time, against a long-run median of 1,598.4× measured over 2.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +2,250.0% against a −56.7% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Fischer Medical Ventures Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 11 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

43.3/100 — rank 7 of 9 in Chemicals - Inorganic · 73% evidence confidence

Fischer Medical Ventures Ltd scores 43.3 out of 100 against the 9 companies it is compared with in Chemicals - Inorganic, ranking 7. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -35.6% and the one-year return is -56.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.

The four contributions add to the total exactly: 25.1 + 6.3 + 8.9 + 3 = 43.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Fischer Medical Ventures Ltd reported ₹97.7 Cr of revenue in the Mar 26 quarter, +98.8% year on year. That is the 5th straight quarter of year-on-year growth. The last full year, FY26, came in at ₹309 Cr. The last four reported quarters add to ₹309 Cr.

Fischer Medical Ventures Ltd reported ₹97.7 Cr of revenue in the Mar 26 quarter, +98.8% year on year. That is the 5th straight quarter of year-on-year growth. The last full year, FY26, came in at ₹309 Cr. The last four reported quarters add to ₹309 Cr.

FY26 revenue came in at ₹309 Cr (+178.4% on the year). The latest quarter (Mar 26) printed ₹97.7 Cr, +98.8% year on year — the 5th consecutive quarter of year-over-year growth.

Acceleration check: trailing-twelve-month revenue grew +178.8% over the last 4 quarters against +285.3%/yr over the last 8 — rolling over; TTM profit +2,508.4% vs +272.3%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 1.0% this quarter (−4.1 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Fischer Medical Ventures Ltd's operating margin is 1.0% in the Mar 26 quarter, −4.1 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −300.0% to 2,000.0%. The current quarter sits inside that band.

Fischer Medical Ventures Ltd's operating margin is 1.0% in the Mar 26 quarter, −4.1 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −300.0% to 2,000.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 1.0%, −4.1 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −300.0%–2,000.0%.

🚨 Why the margin moved: operating margin went −4.1 pp year on year while gross margin went +9.9 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins slipped — did that reach the bottom line? Next: profit −642.0% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Fischer Medical Ventures Ltd posted a net loss of ₹7.1 Cr in the Mar 26 quarter. Full-year FY26 profit was ₹31.0 Cr. That loss is 7.3% of the quarter's revenue. The same quarter a year earlier earned ₹1.3 Cr. 5 of the last 12 reported quarters were loss-making.

Fischer Medical Ventures Ltd posted a net loss of ₹7.1 Cr in the Mar 26 quarter. Full-year FY26 profit was ₹31.0 Cr. That loss is 7.3% of the quarter's revenue. The same quarter a year earlier earned ₹1.3 Cr. 5 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹−7.1 Cr, −642.0% year on year. On the full year, FY26 printed ₹31.0 Cr (+3,000.0%).

→ Profit rose — but did the cash follow? Next: −574% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years −574% of Fischer Medical Ventures Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−101 Cr of operating cash against ₹31.0 Cr of profit. After ₹14.0 Cr of capital spending, ₹−115 Cr was left as free cash.

FY26: operating cash of ₹−101 Cr against reported profit of ₹31.0 Cr, leaving free cash of ₹−115 Cr after ₹14.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −574% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −574%: the cash cycle stretched 111 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 111 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 111-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Fischer Medical Ventures Ltd's cash conversion cycle runs 111 days in FY26, up from 0 days in FY21. Capital spending ran ₹41.0 Cr over the last 3 years. At FY26 sales of ₹309 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹94.0 Cr sits inside the business at any moment.

FY26: debtors at 342 days, inventory at 32 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 111 days, looser than FY21's 0.

The full loop: cash goes out to suppliers and production on day 0; stock waits 32 days to sell; customers pay about 342 days after that; and suppliers themselves are paid at 263 days — netting out to the 111-day cycle.

In money terms: at FY26 sales of ₹309 Cr, each day of the cycle holds about ₹0.8 Cr — so the 111-day loop keeps roughly ₹94.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹41.0 Cr over the last 3 fiscal years against ₹5.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹3.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 11% and the ROIC − WACC spread is −5.5 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Fischer Medical Ventures Ltd earns a ROCE of 11% in FY26. That is up from a trough of −350% in FY17. Return on invested capital clears the cost of that capital by −5.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 10.0% net margin on 0.46× asset turns.

FY26 ROCE is 11%, recovered from a FY17 trough of −350% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 10.0% net margin × 0.46× asset turns × 1.75× balance-sheet leverage ≈ 8.1% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 6.5% − 12.0% = a −5.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.28.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Fischer Medical Ventures Ltd carries total debt of ₹107 Cr against shareholder equity of ₹387 Cr as of Mar 26, a debt-to-equity of 0.28 — effectively unlevered. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹107 Cr against shareholder equity of ₹387 Cr — a debt-to-equity of 0.28. The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Promoters cut 12.8 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 12.8 points of Fischer Medical Ventures Ltd over 8 quarters, the biggest move on the register. That takes promoters to 62.1% of the company. Foreign institutions moved +0.4 points over the same window, to 5.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −12.8 points over 8 quarters to 62.1%; Foreign institutions: +0.4 points over 8 quarters to 5.5%; Domestic institutions: −0.3 points over 8 quarters to 1.4%.

🚨 Why the register moved: promoters drove it (−12.8 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Fischer Medical Ventures Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions